[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100213477":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":13,"responsibleParty":93,"collaborators":7,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":7,"enrollmentInfo":105,"targetDuration":7,"studyType":108,"phases":7,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":119,"whyStopped":7,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"MedSIR","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Joaquin Gávila, MD","Valencia","PRINCIPAL_INVESTIGATOR",[14,24,31,38,45,52,59,66,73,80,86],{"facility":7,"status":7,"city":15,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":18,"geoPoint":23,"contacts":7},"Barcelona","Spain","ES",{"type":19,"coordinates":20},"Point",[21,22],2.15899,41.38879,{"lat":22,"lon":21},{"facility":7,"status":7,"city":25,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":26,"geoPoint":30,"contacts":7},"Córdoba",{"type":19,"coordinates":27},[28,29],-4.77275,37.89155,{"lat":29,"lon":28},{"facility":7,"status":7,"city":32,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":33,"geoPoint":37,"contacts":7},"Girona",{"type":19,"coordinates":34},[35,36],2.82493,41.98311,{"lat":36,"lon":35},{"facility":7,"status":7,"city":39,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":40,"geoPoint":44,"contacts":7},"Jaén",{"type":19,"coordinates":41},[42,43],-3.79028,37.76922,{"lat":43,"lon":42},{"facility":7,"status":7,"city":46,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":47,"geoPoint":51,"contacts":7},"Madrid",{"type":19,"coordinates":48},[49,50],-3.70256,40.4165,{"lat":50,"lon":49},{"facility":7,"status":7,"city":53,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":54,"geoPoint":58,"contacts":7},"Pamplona",{"type":19,"coordinates":55},[56,57],-1.64323,42.81687,{"lat":57,"lon":56},{"facility":7,"status":7,"city":60,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":61,"geoPoint":65,"contacts":7},"Salamanca",{"type":19,"coordinates":62},[63,64],-3.67975,40.42972,{"lat":64,"lon":63},{"facility":7,"status":7,"city":67,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":68,"geoPoint":72,"contacts":7},"Santiago de Compostela",{"type":19,"coordinates":69},[70,71],-8.54569,42.88052,{"lat":71,"lon":70},{"facility":7,"status":7,"city":74,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":75,"geoPoint":79,"contacts":7},"Seville",{"type":19,"coordinates":76},[77,78],-5.97317,37.38283,{"lat":78,"lon":77},{"facility":7,"status":7,"city":11,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":81,"geoPoint":85,"contacts":7},{"type":19,"coordinates":82},[83,84],-0.37966,39.47391,{"lat":84,"lon":83},{"facility":7,"status":7,"city":87,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":88,"geoPoint":92,"contacts":7},"Zaragoza",{"type":19,"coordinates":89},[90,91],-0.87734,41.65606,{"lat":91,"lon":90},{"type":94,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100213477","clinical-benefit-of-the-treatment-with-trastuzumab-in-combination-with-lapatinib-in-metastatic-breast-cancer-her2-positive-patients-who-has-been-previously-treated-with-trastuzumab-andor-lapatinib-100213477",false,"NCT02056080","Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and\u002For Lapatinib","Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and\u002For Lapatinib","TRASTYVERE","Inclusion Criteria:\n\n* Confirmed diagnosis of metastatic breast cancer HER2-positive phenotype (confirmed by IHC 3 + or FISH positive)\n* Older than 18 years\n* Progressed to at least one prior treatment line for MBC with trastuzumab and \u002F or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes\n* Having the patient's complete medical history that contains all lines antiHER2 therapy treatment\n* Being a patient who initiated the combination of trastuzumab and lapatinib between January 2005 and December 2011\n* Inform the patient and get the signature of the informed consent\n\nExclusion Criteria:\n\n* Not having phenotypic classification of the tumor by IHC or FISH test for HER2\n* Being a patient with HER2-negative phenotype(FISH negative or IHC in range \\[0-2 +\\] without FISH)\n* Being a patient who received the trastuzumab and\u002For lapatinib treatment (TL) in combination with chemotherapy\n* Being a patient who, since January 2012, began TL therapy for metastatic disease.","ALL","18 Years",{"count":106,"type":107},111,"ACTUAL","OBSERVATIONAL","A retrospective, observational, not EPA, multicenter study to evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and\u002For Lapatinib between January 2005 and December 2011",[111],"Breast Neoplasm",[111,113,114,115,116,117,118],"Receptor,HER2","Antineoplastic agent","Antibodies, monoclonal","Trastuzumab, Lapatinib","Protein kinase inhibitors","quinazolines","COMPLETED","2019-09-06",{"date":122,"type":107},"2019-09-09",{"date":124,"type":107},"2013-01",{"date":126,"type":107},"2014-01",{"name":5,"class":6},11]